Would you consider TKI discontinuation in a patient who has negative BCR transcripts on Bosutinib?
Data exists for imatinib Dasatinib and nolotinib
Answer from: Medical Oncologist at Community Practice
Yes, I would certainly consider it provided they meet the criteria. Those criteria would be no different than for the other TKI. It is generally considered that the expectations are the same for all TKIs (with more patients eligible with second generation TKI than with imatinib). Most of this is ext...
Sign in or Register to read more